Application of sintilimab combined with anlotinib hydrochloride in the clinical treatment of microsatellite stable colorectal cancer

Table 4 Comparison of the levels of T lymphocyte subsets

Indicators	Time	Observation group, n = 46	Control group, n = 46	t	P value
CD4+ in %	Before treatment	28.40 ± 2.46	28.35 ± 2.50	0.097	0.923
	After treatment	36.45 ± 5.511	32.21 ± 4.011	4.220	0.000
CD8+ in %	Before treatment	27.26 ± 2.36	27.35 ± 2.47	0.179	0.859
	After treatment	21.32 ± 1.101	24.20 ± 1.541	10.321	0.000
CD4+/CD8+ in %	Before treatment	1.04 ± 0.44	1.03 ± 0.47	0.123	0.902
	After treatment	1.71 ± 0.581	1.33 ± 0.521	3.309	0.001

¹Denotes a comparison with the pretreatment values. Data are mean ± SD.